This is the second webinar in the BioMedical SIG webinar series, “From Research to Development – Paths to Cross the Valley of Death in Life Sciences”, which showcases initiatives available to European KTOs to maturate technologies with potential in TRL and CRL, without the creation of a spin-off.
In this session, speakers Peter Nussbaumer and Gernot Faustmann will present the KHAN/w4i/LDC initiative. This collaborative drug discovery platform facilitates the translation of world-class science into innovative therapies for the benefit of patients. Their mission is to create value through cooperative drug development partnerships with academic innovators in Europe. They focus on first-in-class therapies for attractive markets with a high unmet medical need.
This webinar is organised by the BioMedical SIG and supported by UCB. Join the BioMedical SIG to stay informed.
I really like the course and the networking. I would like to come again.
Nancy Goel
Qatar Foundation, Qatar
ASTP has attained a unique position that has turned it into a highly valued player on the global technology transfer scene.
Koenraad Debackere
KU Leuven, Belgium
This course gives an in-depth understanding on managing contract portfolio, including research contracts, license agreements, and other collaboration agreements.
Ram Siddappa
Erasmus MC, Netherlands
ASTP brought the right structure and terminology to my knowledge of technology licensing.
René Widmer
ETH Transfer, Switzerland
There was ample opportunity to learn from colleagues through the workshop sessions or more formally through speakers either sharing their years of experience or their state of the art research. Well worth attending.
John Gleeson
University of Limerick, Ireland
Join our newsletter and get the latest news